Related Experiment Videos
Protective effect of tulobuterol on methacholine-induced bronchospasm in asthmatic children
Insights
Tulobuterol hydrochloride effectively reduces methacholine-induced bronchospasm in children with asthma. This study found that tulobuterol HCl significantly increased the dose of methacholine needed to cause airway narrowing in pediatric asthma patients.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
- Respiratory Medicine
Background:
- Asthma is a chronic respiratory disease affecting children, characterized by airway inflammation and hyperresponsiveness.
- Methacholine challenge tests are used to assess airway hyperresponsiveness in asthma.
- Tulobuterol hydrochloride is a bronchodilator used in asthma management.
Purpose of the Study:
- To evaluate the efficacy of tulobuterol hydrochloride in reducing methacholine-induced bronchospasm in children with asthma.
- To compare the effects of tulobuterol hydrochloride versus placebo on airway responsiveness.
Main Methods:
- A single-blind, placebo-controlled trial was conducted with 19 asthmatic children aged 10-14 years.
- Participants underwent methacholine inhalation tests on two consecutive days.
- On day one, patients received an oral placebo; on day two, they received an oral dose of tulobuterol hydrochloride.
Main Results:
- The cumulative methacholine dose causing at least a 20% decrease in forced expiratory volume in 1 second (FEV1) was significantly higher after tulobuterol administration compared to placebo.
- Tulobuterol hydrochloride demonstrated a significant protective effect against methacholine-induced bronchospasm.
Conclusions:
- Tulobuterol hydrochloride is effective in reducing methacholine-induced bronchospasm in children with stable asthma.
- The findings support the use of tulobuterol hydrochloride for managing airway hyperresponsiveness in pediatric asthma.
Abstract:
In a single-blind, placebo-controlled trial 19 asthmatic children aged 10-14 years were studied during a stable phase of the disease. All patients were tested with a methacholine inhalation test on two consecutive days, on the first day after oral administration of a placebo, and on the second day following an oral dose of tulobuterol HCl. The cumulative methacholine dose required to produce at least a 20% decrease in FEV1 was significantly higher after tulobuterol than after the placebo. It is concluded that tulobuterol HCl reduces methacholine-induced bronchospasm in children.